Free tool
FAERS Monitor: Dyna-Hex 2
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019422 or its brand name (Dyna-Hex 2, Chlorhexidine Gluconate). Reports on generic versions are filed under their own applications.
Reports
7,749
Serious
6,519
84% of reports
Hospitalization
3,787
Death reported
2,710
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
Nothing to show.
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 28 |
| 2005 | 19 |
| 2006 | 21 |
| 2007 | 38 |
| 2008 | 89 |
| 2009 | 95 |
| 2010 | 151 |
| 2011 | 160 |
| 2012 | 163 |
| 2013 | 64 |
| 2014 | 84 |
| 2015 | 132 |
| 2016 | 241 |
| 2017 | 276 |
| 2018 | 297 |
| 2019 | 313 |
| 2020 | 405 |
| 2021 | 681 |
| 2022 | 605 |
| 2023 | 510 |
| 2024 | 1,323 |
| 2025 | 1,535 |
| 2026 | 519 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,410 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.